127 related articles for article (PubMed ID: 27559738)
1. HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.
Ecker BL; Taylor L; Zhang PJ; Furth EE; Ginsberg GG; McMillan MT; Datta J; Czerniecki BJ; Roses RE
PLoS One; 2016; 11(8):e0161781. PubMed ID: 27559738
[TBL] [Abstract][Full Text] [Related]
2. Her-2 Expression in Gastroesophageal Intestinal Metaplasia, Dysplasia, and Adenocarcinoma.
Almhanna K; Rosa M; Henderson-Jackson E; Jiang K; Shamekh R; Sayegh Z; Malafa MP; Coppola D
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):633-638. PubMed ID: 26186253
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
4. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
5. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine in Barrett's mucosa and adenocarcinomas of the gastroesophageal junction.
Koppert LB; Wijnhoven BP; Tilanus HW; Stijnen T; Van Dekken H; Dinjens WN
Int J Surg Pathol; 2004 Apr; 12(2):117-25. PubMed ID: 15173916
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression.
Skacel M; Petras RE; Gramlich TL; Sigel JE; Richter JE; Goldblum JR
Am J Gastroenterol; 2000 Dec; 95(12):3383-7. PubMed ID: 11151865
[TBL] [Abstract][Full Text] [Related]
8. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
9. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
[TBL] [Abstract][Full Text] [Related]
10. High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.
Abu-Farsakh S; Wu T; Lalonde A; Sun J; Zhou Z
BMC Gastroenterol; 2017 Feb; 17(1):33. PubMed ID: 28212604
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus.
Sarbia M; Bektas N; Müller W; Heep H; Borchard F; Gabbert HE
Cancer; 1999 Dec; 86(12):2597-601. PubMed ID: 10594854
[TBL] [Abstract][Full Text] [Related]
12. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-beta is expressed in Barrett's metaplasia and associated adenocarcinoma of the esophagus.
Akgun H; Lechago J; Younes M
Anticancer Res; 2002; 22(3):1459-61. PubMed ID: 12168823
[TBL] [Abstract][Full Text] [Related]
14. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue.
Sabo E; Meitner PA; Tavares R; Corless CL; Lauwers GY; Moss SF; Resnick MB
Clin Cancer Res; 2008 Oct; 14(20):6440-8. PubMed ID: 18927283
[TBL] [Abstract][Full Text] [Related]
15. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.
Srivastava A; Hornick JL; Li X; Blount PL; Sanchez CA; Cowan DS; Ayub K; Maley CC; Reid BJ; Odze RD
Am J Gastroenterol; 2007 Mar; 102(3):483-93; quiz 694. PubMed ID: 17338734
[TBL] [Abstract][Full Text] [Related]
16. SOX2 as a novel marker to predict neoplastic progression in Barrett's esophagus.
van Olphen S; Biermann K; Spaander MC; Kastelein F; Steyerberg EW; Stoop HA; Bruno MJ; Looijenga LH
Am J Gastroenterol; 2015 Oct; 110(10):1420-8. PubMed ID: 26323187
[TBL] [Abstract][Full Text] [Related]
17. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
Dorer R; Odze RD
Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
[TBL] [Abstract][Full Text] [Related]
18. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression.
Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR
Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 overexpression in gastric and gastroesophageal junction adenocarcinoma in patients seen at the University Teaching Hospital, Lusaka, Zambia.
Kasochi C; Julius P; Mweemba I; Kayamba V
Afr Health Sci; 2020 Dec; 20(4):1857-1864. PubMed ID: 34394249
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus.
Geddert H; Heep HJ; Gabbert HE; Sarbia M
Cancer; 2002 Jan; 94(1):212-8. PubMed ID: 11815979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]